Page last updated: 2024-08-23

buserelin and nilutamide

buserelin has been researched along with nilutamide in 26 studies

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-199019 (73.08)18.7374
1990's3 (11.54)18.2507
2000's4 (15.38)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Campus, G; D'Atri, M; De Lisa, A; Migliari, R; Scarpa, RM; Serra, A; Usai, E; Zucca, I1
Denis, L1
Billebaud, T; Costa, P; Dahan, R; Fiet, J; Grise, P; Husson, JM; Kuhn, JM; Louis, JF; Moulonguet, A; Navratil, H1
de Jong, FH; Lamberts, SW; Uitterlinden, P1
Fiet, J; Moguilewsky, M; Raynaud, JP; Tournemine, C1
Bélanger, A; Brun, D; Dupont, A; Gagné, C; Giguère, M; Labrie, F; Lupien, PJ; Moorjani, S1
Cotard, M; Moguilewsky, M; Proulx, L; Raynaud, JP; Tournemine, C1
Béland, G; Elhilali, M; Fradet, Y; Laroche, B; Ramsey, EW; Tewari, HD; Venner, PM1
Navratil, H1
Hubert, J; Lamy, P; Seigneur, J; Trechot, PF1
Moguilewsky, M; Tournemine, C1
Béland, G; Elhilali, M; Fradet, Y; Laroche, B; Ramsey, EW; Trachtenberg, J; Venner, PM1
Bélanger, A; Dupont, A; Labrie, F1
Bélanger, A; Cusan, L; Kelly, PA; Labrie, F; Raynaud, JP; Séguin, C1
Belanger, A; Cusan, L; Dupont, A; Fazekas, AT; Husson, JM; Labrie, F; Lefebvre, FA; Raynaud, JP1
Belanger, A; Cusan, L; Dupont, A; Emond, JP; Fazekas, AT; Husson, JM; Laberge, JG; Labrie, F; Lefebvre, FA; Monfette, G; Raynaud, JP1
Belanger, A; Dupont, A; Fazekas, AT; Gareau, J; Husson, JM; Labrie, F; Lacoursiere, Y; Monfette, G; Raynaud, JP; Sandow, J1
Faure, N; Fazekas, AT; Jean, C; Laroche, B; Lemay, A; Plante, R; Robert, G; Roy, R; Thabet, M1
Belanger, A; Dupont, A; Labrie, F; Lefebvre, FA; Raynaud, JP1
Bélanger, A; Dupont, A; Emond, J; Labrie, F; Monfette, G1
Belanger, A; Cusan, L; Dupont, A; Emond, JP; Fazekas, AT; Husson, JM; Laberge, JG; Labrie, F; Lacourciere, Y; Monfette, G; Raynaud, JP1
Doré, JC; Fiet, J; Gô, AL; Ojasoo, T; Raynaud, JP1
Chander, S; Cheung, P; Choo, R; Danjoux, C; Deboer, G; Loblaw, A; Morton, G; Pearce, A; Szumacher, E; Woo, T1
Brower, V1
Cheung, P; Choo, R; Danjoux, C; Gardner, S; Loblaw, DA; Morton, G; Pearse, M; Szumacher, E2

Reviews

2 review(s) available for buserelin and nilutamide

ArticleYear
What is an antiandrogen and what is the physiological and pharmacological rationale for combined "castration" + "antiandrogen" therapy.
    Progress in clinical and biological research, 1987, Volume: 243A

    Topics: Androgen Antagonists; Animals; Buserelin; Combined Modality Therapy; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms; Rats; Receptors, Steroid

1987
[New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Journal de pharmacologie, 1983, Volume: 14 Suppl 3

    Topics: Acid Phosphatase; Androgen Antagonists; Buserelin; Drug Synergism; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Hormones; Humans; Imidazoles; Imidazolidines; Male; Prostate; Prostatic Neoplasms

1983

Trials

6 trial(s) available for buserelin and nilutamide

ArticleYear
Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    The New England journal of medicine, 1989, Aug-17, Volume: 321, Issue:7

    Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Evaluation; Humans; Imidazoles; Imidazolidines; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Prostatic Neoplasms; Testosterone

1989
Total androgen blockade vs orchiectomy in stage D2 prostate cancer.
    Progress in clinical and biological research, 1987, Volume: 243A

    Topics: Androgen Antagonists; Buserelin; Clinical Trials as Topic; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms

1987
Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
    Progress in clinical and biological research, 1987, Volume: 243A

    Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Clinical Trials as Topic; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms

1987
Total androgen blockade for metastatic cancer of the prostate.
    American journal of clinical oncology, 1988, Volume: 11 Suppl 2

    Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Placebos; Prognosis; Prostatic Neoplasms; Random Allocation; Remission Induction

1988
Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy.
    The Prostate, 1993, Volume: 23, Issue:4

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Buserelin; Double-Blind Method; Hormones; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prostatic Neoplasms

1993
Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
    International journal of radiation oncology, biology, physics, 2009, Nov-15, Volume: 75, Issue:4

    Topics: Aged; Androgen Antagonists; Buserelin; Drug Administration Schedule; Follow-Up Studies; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Salvage Therapy; Survival Rate; Time Factors

2009

Other Studies

18 other study(ies) available for buserelin and nilutamide

ArticleYear
Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
    Archivio italiano di urologia, nefrologia, andrologia : organo ufficiale dell'Associazione per la ricerca in urologia = Urological, nephrological, and andrological sciences, 1991, Volume: 63, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Vision, Ocular

1991
Maximal androgen blockade in prostatic cancer.
    Scandinavian journal of urology and nephrology. Supplementum, 1991, Volume: 138

    Topics: Androgen Antagonists; Buserelin; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Orchiectomy; Prostatic Neoplasms

1991
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Cancer research, 1988, Nov-01, Volume: 48, Issue:21

    Topics: Adrenocorticotropic Hormone; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Goserelin; Imidazoles; Imidazolidines; Ketoconazole; Luteinizing Hormone; Male; Orchiectomy; Organ Size; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains

1988
Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
    Journal of steroid biochemistry, 1986, Volume: 24, Issue:1

    Topics: Androgen Antagonists; Animals; Buserelin; Diethylstilbestrol; Humans; Imidazoles; Imidazolidines; Kinetics; Male; Orchiectomy; Organ Size; Prostate; Prostatic Neoplasms; Rats; Receptors, Androgen; Receptors, Cell Surface; Receptors, LHRH; Receptors, Steroid; Testosterone

1986
Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma.
    Metabolism: clinical and experimental, 1987, Volume: 36, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Humans; Imidazoles; Imidazolidines; Lipoproteins, HDL; Male; Prostatic Neoplasms

1987
Pulmonary complications of hormone treatment in prostate carcinoma.
    Chest, 1988, Volume: 93, Issue:5

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Pulmonary Fibrosis

1988
The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist buserelin in the rat.
    American journal of clinical oncology, 1988, Volume: 11 Suppl 2

    Topics: Administration, Oral; Androgen Antagonists; Animals; Buserelin; Drug Synergism; Imidazoles; Imidazolidines; Injections, Subcutaneous; Male; Orchiectomy; Prostate; Rats; Rats, Inbred Strains; Testis; Testosterone

1988
Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
    The Journal of clinical endocrinology and metabolism, 1984, Volume: 59, Issue:3

    Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Androgens; Buserelin; Castration; Combined Modality Therapy; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Imidazoles; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Testosterone

1984
Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat.
    Molecular and cellular endocrinology, 1981, Volume: 21, Issue:1

    Topics: Animals; Buserelin; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Imidazoles; Imidazolidines; Luteinizing Hormone; Male; Organ Size; Prostate; Rats; Receptors, Cell Surface; Receptors, LH; Seminal Vesicles; Testosterone

1981
New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
    Hormone research, 1983, Volume: 18, Issue:1-3

    Topics: Androgen Antagonists; Animals; Buserelin; Drug Therapy, Combination; Gonadal Steroid Hormones; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Rats; Testis

1983
New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.
    Journal of steroid biochemistry, 1983, Volume: 19, Issue:1C

    Topics: Androgen Antagonists; Animals; Buserelin; Castration; Dihydrotestosterone; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Hormones; Humans; Imidazoles; Imidazolidines; Male; Prostate; Prostatic Neoplasms; Rats; Seminal Vesicles; Testosterone

1983
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
    The Prostate, 1983, Volume: 4, Issue:6

    Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Hormones; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Radiography; Testosterone

1983
Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
    The Prostate, 1983, Volume: 4, Issue:6

    Topics: Acid Phosphatase; Aged; Androgen Antagonists; Bone and Bones; Buserelin; Castration; Drug Therapy, Combination; Hormones; Humans; Imidazoles; Imidazolidines; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Radiography; Testis; Testosterone

1983
Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.
    Proceedings of the National Academy of Sciences of the United States of America, 1984, Volume: 81, Issue:12

    Topics: Acid Phosphatase; Adenocarcinoma; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Testosterone

1984
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
    Clinical and investigative medicine. Medecine clinique et experimentale, 1982, Volume: 5, Issue:4

    Topics: Adenocarcinoma; Androgen Antagonists; Animals; Bone Neoplasms; Buserelin; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Rats

1982
How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
    The Canadian journal of urology, 2005, Volume: 12, Issue:1

    Topics: Aged; Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Buserelin; Clinical Trials, Phase II as Topic; Hemoglobins; Humans; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Radiotherapy, Adjuvant; Sickness Impact Profile; Testosterone

2005
Watchful waiting beats androgen deprivation therapy in early prostate cancer.
    Journal of the National Cancer Institute, 2008, Nov-05, Volume: 100, Issue:21

    Topics: Aged; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Buserelin; Drug Prescriptions; Flutamide; Humans; Imidazolidines; Leuprolide; Male; Patient Education as Topic; Patient Satisfaction; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis

2008
Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
    International journal of radiation oncology, biology, physics, 2009, Oct-01, Volume: 75, Issue:2

    Topics: Aged; Androgen Antagonists; Buserelin; Combined Modality Therapy; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Survival Rate

2009
chemdatabank.com